No significant associations between the VEGF +936 C/T polymorphism and response to chemotherapy in CRC were identified in any comparison models, including C allele vs. T allele (OR = 0.81, 95% CI 0.56–1.17, P = 0.26), CC vs. CT+TT (OR = 0.76, 95% CI 0.54–1.09, P = 0.81), CC+CT vs. TT (OR = 0.94, 95% CI 0.31–2.91, P = 0.92), CC vs. TT (OR = 0.86, 95% CI 0.28–2.68, P = 0.80), CC vs. CT (OR = 0.74, 95% CI 0.48–1.16, P = 0.19), or CT vs. TT (OR = 1.15, 95% CI 0.36–3.70, P = 0.82) (Table 2). This evidence concerns the gene VEGFA and colorectal carcinoma.